The value of clinical research with modern medicines in New Zealand: Economic contribution and wide-ranging benefits
In: http://hdl.handle.net/11540/12091
NZIER was asked to determine the economic contribution of clinical trials to the New Zealand economy in terms of: 1. Direct economic contribution; 2. Indirect economic contribution 3. Total economic contribution. We were also asked to provide a qualitative assessment of the benefits to New Zealand's health sector from conducting clinical trials in New Zealand. To ensure reliability of our analysis, we have narrowed our scope to pharmaceutical-type clinical trials recommended for approval by the Health Resource Council's (HRC) Standing Committee on Therapeutic Trials (SCOTT) (henceforth, 'SCOTT trials'). These trials are exclusively of interventions that meet the definition of "new medicines" under New Zealand legislation. This means our estimates are conservative as they do not capture the entire clinical trials sector in New Zealand.